tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

LTR Pharma Boosts Stake in LevOmega to 43% with A$1M Investment

Story Highlights
  • LTR Pharma increased its ownership in LevOmega to ~43% with a A$1M investment.
  • The investment supports LevOmega’s sustainable omega-3 product development amid fish oil supply challenges.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
LTR Pharma Boosts Stake in LevOmega to 43% with A$1M Investment

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

The latest update is out from LTR Pharma Limited ( (AU:LTP) ).

LTR Pharma Limited has increased its stake in LevOmega Pty Ltd to approximately 43% through a strategic A$1 million investment. This move aims to bolster LevOmega’s development of sustainable, pharmaceutical-grade omega-3 products, addressing the global demand for alternatives to traditional fish oil sources, which face sustainability challenges. The investment aligns with LTR Pharma’s strategy to support scalable solutions for global sustainability issues while complementing its core pharmaceutical pipeline.

More about LTR Pharma Limited

LTR Pharma is a commercial-stage pharmaceutical company focused on delivering innovative therapies for unmet medical needs through its proprietary intranasal drug delivery platform. The company has commercialized treatments in Australia and is expanding into the US and other markets. Its lead products include SPONTAN® and ROXUS®, intranasal sprays for erectile dysfunction, and OROFLOW®, under development for Oesophageal Motility Disorders.

Average Trading Volume: 889,266

Technical Sentiment Signal: Strong Buy

See more insights into LTP stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1